UBS AM
NTLA icon

UBS AM’s Intellia Therapeutics NTLA Stock Holding History

UBS AM’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.29M Buy
312,809
+28,851
+10% +$404K ﹤0.01% 1585
2026
Q1 		$3.64M Buy
283,958
+44,711
+19% +$570K ﹤0.01% 1733
2025
Q4 		$2.15M Sell
239,247
-2,035
-0.8% -$28K ﹤0.01% 1860
2025
Q3 		$4.17M Sell
241,282
-396,579
-62% -$4.88M ﹤0.01% 1454
2025
Q2 		$5.98M Buy
637,861
+116,155
+22% +$954K ﹤0.01% 1622
2025
Q1 		$3.71M Buy
521,706
+38,521
+8% +$389K ﹤0.01% 1715
2024
Q4 		$5.63M Buy
483,185
+23,173
+5% +$362K ﹤0.01% 1549
2024
Q3 		$9.45M Sell
460,012
-52,297
-10% -$1.21M ﹤0.01% 1250
2024
Q2 		$11.5M Buy
512,309
+132,671
+35% +$3.16M ﹤0.01% 1078
2024
Q1 		$10.4M Sell
379,638
-52,374
-12% -$1.45M ﹤0.01% 976
2023
Q4 		$13.2M Buy
432,012
+24,627
+6% +$708K 0.01% 901
2023
Q3 		$12.9M Sell
407,385
-11,340
-3% -$440K 0.01% 874
2023
Q2 		$15.6M Hold
418,725
– – 0.01% 822
2023
Q1 		$15.6M Buy
418,725
+25,481
+6% +$999K 0.01% 822
2022
Q4 		$13.7M Sell
393,244
-9,831
-2% -$467K 0.01% 841
2022
Q3 		$22.6M Buy
403,075
+31,670
+9% +$1.96M 0.01% 731
2022
Q2 		$19.2M Buy
371,405
+52,001
+16% +$2.64M 0.01% 747
2022
Q1 		$23.2M Buy
319,404
+30,815
+11% +$2.61M 0.01% 808
2021
Q4 		$34.1M Sell
288,589
-727
-0.3% -$91.1K 0.01% 759
2021
Q3 		$38.8M Buy
289,316
+15,824
+6% +$2.4M 0.02% 697
2021
Q2 		$44.3M Buy
273,492
+42,301
+18% +$3.29M 0.02% 662
2021
Q1 		$18.6M Sell
231,191
-49,808
-18% -$3.34M 0.01% 881
2020
Q4 		$15.3M Buy
280,999
+215,922
+332% +$7.84M 0.01% 923
2020
Q3 		$1.29M Buy
65,077
+5,136
+9% +$107K ﹤0.01% 1740
2020
Q2 		$1.26M Buy
59,941
+11,148
+23% +$189K ﹤0.01% 1705
2020
Q1 		$597K Buy
48,793
+7,650
+19% +$103K ﹤0.01% 1906
2019
Q4 		$604K Sell
41,143
-1,749
-4% -$24.3K ﹤0.01% 2163
2019
Q3 		$573K Buy
42,892
+24,637
+135% +$393K ﹤0.01% 2223
2019
Q2 		$299K Buy
+18,255
New +$287K ﹤0.01% 2411
2018
Q4 		– Sell
-8,635
Closed -$247K – 2807
2018
Q3 		$247K Buy
+8,635
New +$251K ﹤0.01% 2350

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

UBS AM's NTLA Position: Q2 2026 in Review

UBS AM increased its Intellia Therapeutics (NTLA) stake by 10% in Q2 2026, buying an estimated $404K and bringing the position to 312,809 shares worth $5.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1585.

UBS AM first reported a position in NTLA in Q3 2018 and has held it in 30 quarters since. The position peaked at $44.3M in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • UBS AM held 312,809 shares of Intellia Therapeutics worth $5.29M as of Q2 2026.
  • UBS AM bought 28,851 Intellia Therapeutics shares in Q2 2026, an estimated $404K.
  • Intellia Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1585 holding.
  • UBS AM first reported a position in Intellia Therapeutics in Q3 2018 and has held it in 30 quarters since.
  • UBS AM's Intellia Therapeutics position peaked at $44.3M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.